CASTLE BIOSCIENCES INC

CSTL
About the company

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma.

Country: United StatesPrice: $33.79Market Cap: $1.0B

Investment snapshot

0%positive consensus
Scored 1d ago

Positive

0

BUY / PASS

Neutral / negative

1 / 15

NEUTRAL / FAIL

Median fair value

$17.36

-48.6% vs price

Models with upside

1 / 17

Positive margin of safety

Strongest signal

10 of 12 pass — Buffett and Marks object

Key risk

All 13 investors flag CSTL's valuation

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2002 (Top 64.6%)FAILFAILFAILFAILFAILFAILFAILFAILFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/A-94.6%-1133.2%N/AN/A+1.0%N/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

TTM ended 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-26

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-02-26

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Qualitative assessment

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-02-26

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Where It Passes

  • Debt & Leverage83% pass✓ 13✗ 2▾

    10 of 12 pass — Buffett and Marks object

    LT Debt vs Net Current AssetsLT Debt $5.9M vs NCA $289.2M
    ✓GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: 0.02, IC: -51.2x
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0.02
    ✓Lynch< 0.33
    Cash - Long-term Debt$72.1M
    ✓LynchPositive preferred
    LT Debt / Total Assets Change1.83% -> 1.67%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities5.28
    ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity0.02
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Debt Levels0.02
    ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=-51.2x, D/EBITDA=N/A
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0.02
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.0211; #753/4210 (top 17.9%)
    ✓AsnessTop 30% of eligible cross-section

Where It Falls Short

  • Valuation0% pass✗ 28▾

    All 13 investors flag CSTL's valuation

    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio2.1x
    ✗Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value-2.9%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-2.9%, ROC=-8.6%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)15.6x
    ✗Dreman< 8x
    Price / Book Value per Share2.1x
    ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Valuation ReasonablenessOE Yield=-1.9%
    ✗MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldFCF Yield=2.7%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/B=2.1x
    ✗MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per Share35.5x
    ✗Ackman<= 25
    Price vs. Trailing Low223% of trailing low ($15.15)
    ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization-2.21%; #3586/6340 (top 56.6%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+0.4594; #3036/6449 (top 47.1%)
    ✗AsnessTop 30% of eligible cross-section
    Price / Diluted EPS
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share2.71x
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change-4.8%
    ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+0.3622; #3059/5247 (top 58.3%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization+0.38%; #2473/4519 (top 54.7%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date+46.09%; #704/6202 (top 11.4%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Verdicts0% pass✗ 16▾

    Split decision: 15 FAIL · 1 NEUTRAL

    Overall verdict
    ✗GrahamFAIL (3/9)✗BuffettFAIL (0/9)✗LynchFAIL (2/7)✗GreenblattRank #2002✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (3/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (2/6)✗MarksFAIL (0/5)✗AckmanFAIL (3/9)✗TempletonFAIL (3/8)✗SleepFAIL (2/6)✗AsnessFAIL (Rank #1333/2370 (Top 56.2%))✗NeffFAIL (2/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
  • Profitability6% pass✓ 4✗ 31▾

    15 of 16 flag CSTL's profitability — Graham, Buffett, Lynch +12 more

    Positive EPS (10 years)1/9 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)2/9 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-8.0%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)-12.4% (latest)
    ✗BuffettStable or rising over 10 years
    Free Cash Flow Proxy$-19.4M
    ✗BuffettPositive and growing
    Earnings Variance (10-yr CoV)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE-4.8%
    ✗Lynch> 15%
    EBIT / Enterprise Value-2.9%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-2.9%, ROC=-8.6%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets-4.18%
    ✗PiotroskiROA > 0
    ROA Change YoY3.43% -> -4.18% (delta: -7.61%)
    ✗PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=11.12%, ROA=-4.18%
    ✓PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY81.9% -> 79.4%
    ✗PiotroskiImproved YoY
    Pre-Tax Income / Revenue
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity-4.8%
    ✗Dreman> 12%
    Margin of SafetyP/B=2.1x
    ✗PabraiP/B < 1.5 or P/E < 15
    Return on Equity-5.3% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency2/8 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue-7.4%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity-4.8%
    ✗Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-30.9% (2023) -> -12.4% (2025)
    ✓TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 79.5% -> 79.4%, operating margin -30.9% -> -12.4%
    ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization-2.21%; #3586/6340 (top 56.6%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+47.22%; #733/3702 (top 19.8%)
    ✓AsnessTop 30% of eligible cross-section
    Net income / positive book equity-4.81%; #3200/5226 (top 61.2%)
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.0653; #2914/5884 (top 49.5%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years1/8 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Growth13% pass✓ 3✗ 10▾

    7 of 8 flag CSTL's growth — Graham, Lynch, Dreman +4 more

    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthInv: 20.0% vs Rev: 9.8%
    ✗LynchInventory growth < Revenue growth
    EPS Growth Direction
    ✗DremanPositive over recent years
    EPS CAGR
    ✗Dreman> 5% annualized
    Positive Net Income Frequency2/8 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth51.1%
    ✓Ackman>= 5%
    Positive EPS Growth Frequency2/5 years with positive EPS growth
    ✗AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 79.5% -> 79.4%, operating margin -30.9% -> -12.4%
    ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR40.6%
    ✓SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
  • Cash Flow20% pass✓ 3✗ 9▾

    8 of 10 flag CSTL's cash flow — Buffett, Lynch, Dreman +5 more

    Free Cash Flow Proxy$-19.4M
    ✗BuffettPositive and growing
    FCF Positive and Growing$4.0M
    ✗LynchPositive and growing
    Operating Cash Flow$64.3M
    ✓PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=11.12%, ROA=-4.18%
    ✓PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)15.6x
    ✗Dreman< 8x
    P/E or FCF YieldFCF Yield=2.7%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive4/8 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap0.4%
    ✗Ackman>= 4%
    Price / FCF per Share35.5x
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency4/8 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$4.0M
    ✓Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization+0.38%; #2473/4519 (top 54.7%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Efficiency25% pass✓ 2✗ 9▾

    6 of 8 flag CSTL's efficiency — Buffett, Greenblatt, Piotroski +3 more

    Current Ratio5.28
    ✓Graham>= 2.0
    ROIC (3-5 yr avg)-17.0%
    ✗Buffett> 10%
    ROIC - WACC-27.0%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)-8.6%
    ✗Greenblatt> 25%
    Current Ratio Change YoY7.29 -> 5.26
    ✗PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY0.63x -> 0.59x
    ✗PiotroskiImproved YoY
    Current Assets / Current Liabilities5.28
    ✓Dreman> 1.5
    Return on Invested Capital-4.5%
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=-13.7%; FY2024: ROIC=1.5%; FY2025: ROIC=-7.0%
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROICN/A (non-positive net income)
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/5 years above 12% (latest -7.0%)
    ✗SleepROIC > 12% in a majority of years
  • Valuation models33% pass✓ 1✗ 2▾

    Models split on CSTL at $33.79 — fair values range $2.74–$34.13

    Munger fair value$17.36
    ✗Munger-94.6% margin vs $33.79
    Pabrai fair value$2.74
    ✗Pabrai-1133.2% margin vs $33.79
    Ackman fair value$34.13
    ✓Ackman+1.0% margin vs $33.79

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Healthcare
SIC Sector: Health Services
Size: Small Cap($1.0B)
Revenue: $344.2M+3.7% YoY
Net Income: $24.2M-232.4% YoY

Financial Snapshot

Operating Margin-12.4%
Return on Equity-5.1%
Debt / Equity0.02
Current Ratio5.26
EPS (Diluted)$-0.83
Shares Retired−4.3% / −8.3% 2y

Similar Companies

HCAHCA Healthcare, Inc.
$104.2B
THCTENET HEALTHCARE CORP
$22.8B
GHGuardant Health, Inc.
$20.5B
EXASEXACT SCIENCES CORP
$20.0B

Shareholder Return

Fiscal 2025

Issued 4.3% of shares last year, 8.3% issued over two.

Buybacks
—
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-09-30

2025-10-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: revenue, net income, operating income, ebit, interest expense, operating cash flow, depreciation amortization, capex.

Q3 FY 2026

2026-07-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

Q2 FY 2026

2026-04-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

Q1 FY 2026

2026-01-01 – 2026-03-31

Sources
FY 2025
Sources
  • 10-K · 2026-02-26
FY 2024
Sources
  • 10-K · 2025-02-27
FY 2023
Sources
  • 10-K · 2024-02-28
FY 2022
Sources
  • 10-K · 2023-02-28
FY 2021
Sources
  • 10-K · 2022-02-28
Market Cap$1.0Bcurrent------$1.2Best.$806.1Mest.$633.5Mest.$719.7Mest.$1.1Best.
Revenue$377.1M↑10%$102.9M↑24%$103.5M↑20%$83.7M↓5%$344.2M↑4%$332.1M↑51%$219.8M↑60%$137.0M↑46%$94.1M
Operating Income-$28.0M↑20%-$2.7M↑60%-$3.1M↑28%-$18.4M↑34%-$42.8M↓594%$8.7M↑113%-$68.0M↑7%-$72.9M↓82%-$40.1M
Net Income-$23.0M↓88%-$4.1M↓718%-$2.1M↓146%-$14.5M↑44%-$24.2M↓232%$18.2M↑132%-$57.5M↑14%-$67.1M↓115%-$31.3M
EPS (Diluted)--$-0.13↓550%$-0.07↓147%$-0.49↑46%$-0.83↓234%$0.62↑129%$-2.14↑17%$-2.58↓108%$-1.24
Gross Margin————79.4%↓3%81.9%↑3%79.5%↑4%76.6%↓8%83.2%
Operating Margin-7.4%↑27%-2.7%↑68%-3.0%↑40%-22.0%↑31%-12.4%↓576%2.6%↑108%-30.9%↑42%-53.2%↓25%-42.6%
ROE-4.8%↓84%———-5.1%↓228%4.0%↑127%-14.7%↑13%-16.8%↓121%-7.6%
Total Debt$10.1M$10.1M$10.1M$10.1M$10.1M$10.0M$0↓100%$238.0K↑4%$229.0K
Shareholders' Equity$478.4M↑2%$478.4M↑2%$470.0M↑3%$461.4M↑5%$470.9M↑3%$455.8M↑17%$391.3M↓2%$399.1M↓3%$411.7M
Current Ratio5.28↓18%5.28↓18%6.04↓12%6.75↓28%5.26↓28%7.29↑18%6.20↓23%8.09↓43%14.21
Debt / Equity0.02↓2%0.02↓2%0.02↓3%0.02↓4%0.02↓3%0.020.00↓100%0.00↑7%0.00
Operating Cash Flow$39.7M↓36%$19.7M↓13%$15.2M↓27%-$22.1M↓267%$64.3M↓1%$64.9M↑1253%-$5.6M↑86%-$41.7M↓119%-$19.0M
Free Cash Flow$4.0M↓84%$12.2M↑57%$6.6M↓43%-$34.6M↓221%$28.3M↓22%$36.5M↑290%-$19.2M↑59%-$47.3M↓110%-$22.5M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Healthcare

CSTL vs Peers — Financial Grading

Revenue$344.2MBottom 25%
Net Income$24.2MBottom 25%
ROE-5.1%Median
D/E0.02Median
Op. Margin-12.4%Bottom 25%
Curr. Ratio5.26Top 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
HCA Healthcare, Inc.HCA$104.2B$499.05$75.6B$6.8B-112.6%-7.7113.0%0.971/95/93/71/3F-Score 64/11
TENET HEALTHCARE CORPTHC$22.8B$286.03$21.3B$2.4B56.1%3.1216.5%1.761/94/93/73/3F-Score 65/11
Guardant Health, Inc.GH$20.5B$151.70$982.0M$416.3M419.2%-15.14-44.5%4.842/91/91/70/3F-Score 52/11
EXACT SCIENCES CORPEXAS$20.0B$104.91$3.2B$207.9M-8.7%0.00-6.4%2.432/91/93/70/3F-Score 73/11
Fresenius Medical Care AGFMS$11.4B$22.03$23.1B$1.1B7.4%0.819.3%1.265/92/91/70/3F-Score 85/11
UNIVERSAL HEALTH SERVICES INCUHS$11.2B$194.07$17.4B$1.5B20.5%0.6511.5%1.054/96/95/71/3F-Score 76/11
DAVITA INC.DVA$11.0B$174.56$13.6B$746.8M-114.7%-15.7815.0%1.291/94/92/71/3F-Score 73/11
CHEMED CORPCHE$7.1B$548.20$2.5B$265.2M27.1%—13.4%1.054/97/93/71/3F-Score 66/11